CA2909335A1 — Fenfluramine for use in the treatment of dravet syndrome
Assigned to UNIVERSITY HOSPITAL ANTWERP · Expires 2014-11-06 · 12y expired
What this patent protects
An effective dose of fenfluramine or its pharmaceutically acceptable salt for use in a method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome.
USPTO Abstract
An effective dose of fenfluramine or its pharmaceutically acceptable salt for use in a method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.